Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 10, 2022 07:30 ET | Source: Graybug Vision, Inc.

Graybug Vision Reports Full Year 2021 Financial Results and Recent Corporate Developments

BALTIMORE, March 10, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
February 03, 2022 07:30 ET | Source: Graybug Vision, Inc.

Graybug to Participate in Three Upcoming Medical and Investor Conferences

BALTIMORE, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
January 20, 2022 07:30 ET | Source: Graybug Vision, Inc.

Graybug Vision Makes Key Hires to Further Build Momentum Behind its Pipeline

BALTIMORE, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
November 15, 2021 16:05 ET | Source: Graybug Vision, Inc.

Graybug Vision to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference

BALTIMORE, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
November 11, 2021 16:04 ET | Source: Graybug Vision, Inc.

Graybug Vision Announces Financial Results for the Three and Nine Months Ended September 30, 2021, and Recent Corporate Developments

BALTIMORE, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
November 01, 2021 07:30 ET | Source: Graybug Vision, Inc.

Graybug Vision to Participate in the American Academy of Ophthalmology 2021 Annual Meeting

BALTIMORE, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
September 30, 2021 16:05 ET | Source: Graybug Vision, Inc.

Graybug Vision to Participate in the Annual Ophthalmology Innovation Summit (OIS) Retina@ASRS Conference

BALTIMORE, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
September 28, 2021 07:30 ET | Source: Graybug Vision, Inc.

Graybug Vision Reports Analysis of Data from the Six-Month Extension Study of the ALTISSIMO Phase 2b Trial in Wet AMD

55% of GB-102 1mg patients in Extension Study experienced duration of 12+ months, while maintaining their visual acuity and central retinal thickness73% reduction of injection burden for patients...
September 21, 2021 17:15 ET | Source: Graybug Vision, Inc.

Graybug Vision to Participate in the Cantor Virtual Global Healthcare Conference

BALTIMORE, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
August 11, 2021 16:05 ET | Source: Graybug Vision, Inc.

Graybug Vision Announces Financial Results for the Three and Six Months Ended June 30, 2021, and Recent Corporate Developments

REDWOOD CITY, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right